Alisha M Smith1, Nathan Harper2, Justin A Meunier2, Anne P Branum2, Fabio Jimenez2, Lavanya Pandranki3, Andrew Carrillo4, Charles S Dela Cruz5, Marcos I Restrepo3, Diego J Maselli3, Cynthia G Rather6, Anna H Heisser7, Daniel A Ramirez6, Weijing He2, Robert A Clark8, Charles P Andrews6, Scott E Evans9, Jacqueline A Pugh7, Nu Zhang10, Grace C Lee11, Alvaro G Moreira12, Leopoldo N Segal13, Robert M Ramirez6, Robert L Jacobs6, Muthu Saravanan Manoharan3, Jason F Okulicz14, Sunil K Ahuja15. 1. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex; Foundation for Advancing Veterans' Health Research, South Texas Veterans Health Care System, San Antonio, Tex; Department of Microbiology, Immunology & Molecular Genetics, UT Health San Antonio, San Antonio, Tex; Department of Medicine, UT Health San Antonio, San Antonio, Tex. 2. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex; Foundation for Advancing Veterans' Health Research, South Texas Veterans Health Care System, San Antonio, Tex. 3. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex; Department of Medicine, UT Health San Antonio, San Antonio, Tex. 4. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex; Foundation for Advancing Veterans' Health Research, South Texas Veterans Health Care System, San Antonio, Tex; Department of Medicine, UT Health San Antonio, San Antonio, Tex. 5. Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn. 6. Biogenics Research Chamber, San Antonio, Tex. 7. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex. 8. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex; Department of Microbiology, Immunology & Molecular Genetics, UT Health San Antonio, San Antonio, Tex; Department of Medicine, UT Health San Antonio, San Antonio, Tex. 9. Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Tex. 10. Department of Microbiology, Immunology & Molecular Genetics, UT Health San Antonio, San Antonio, Tex. 11. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex; College of Pharmacy, The University of Texas at Austin, Austin, Tex; Pharmacotherapy Education and Research Center, School of Medicine, UT Health San Antonio, San Antonio, Tex. 12. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex; Division of Neonatology, Department of Pediatrics, UT Health San Antonio, San Antonio, Tex. 13. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New York University School of Medicine, New York, NY. 14. Infectious Disease Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Tex. 15. Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Tex; Foundation for Advancing Veterans' Health Research, South Texas Veterans Health Care System, San Antonio, Tex; Department of Microbiology, Immunology & Molecular Genetics, UT Health San Antonio, San Antonio, Tex; Department of Medicine, UT Health San Antonio, San Antonio, Tex; Department of Biochemistry and Structural Biology, UT Health San Antonio, San Antonio, Tex. Electronic address: ahujas@uthscsa.edu.
Abstract
BACKGROUND: Signifying the 2-compartments/1-disease paradigm, allergic rhinoconjunctivitis (ARC) and asthma (AA) are prevalent, comorbid conditions triggered by environmental factors (eg, house dust mites [HDMs]). However, despite the ubiquity of triggers, progression to severe ARC/AA is infrequent, suggesting either resilience or adaptation. OBJECTIVE: We sought to determine whether ARC/AA severity relates to maladaptive responses to disease triggers. METHODS: Adults with HDM-associated ARC were challenged repetitively with HDMs in an aeroallergen challenge chamber. Mechanistic traits associated with disease severity were identified. RESULTS: HDM challenges evoked maladaptive (persistently higher ARC symptoms), adaptive (progressive symptom reduction), and resilient (resistance to symptom induction) phenotypes. Symptom severity in the natural environment was an imprecise correlate of the phenotypes. Nasal airway traits, defined by low inflammation-effectual epithelial integrity, moderate inflammation-effectual epithelial integrity, and higher inflammation-ineffectual epithelial integrity, were hallmarks of the resilient, adaptive, and maladaptive evoked phenotypes, respectively. Highlighting a crosstalk mechanism, peripheral blood inflammatory tone calibrated these traits: ineffectual epithelial integrity associated with CD8+ T cells, whereas airway inflammation associated with both CD8+ T cells and eosinophils. Hallmark peripheral blood maladaptive traits were increased natural killer and CD8+ T cells, lower CD4+ mucosal-associated invariant T cells, and deficiencies along the TLR-IRF-IFN antiviral pathway. Maladaptive traits tracking HDM-associated ARC also contributed to AA risk and severity models. CONCLUSIONS: Repetitive challenges with HDMs revealed that maladaptation to disease triggers may underpin ARC/AA disease severity. A combinatorial therapeutic approach may involve reversal of loss-of-beneficial-function traits (ineffectual epithelial integrity, TLR-IRF-IFN deficiencies), mitigation of gain-of-adverse-function traits (inflammation), and blocking of a detrimental crosstalk between the peripheral blood and airway compartments. Published by Elsevier Inc.
BACKGROUND: Signifying the 2-compartments/1-disease paradigm, allergic rhinoconjunctivitis (ARC) and asthma (AA) are prevalent, comorbid conditions triggered by environmental factors (eg, house dust mites [HDMs]). However, despite the ubiquity of triggers, progression to severe ARC/AA is infrequent, suggesting either resilience or adaptation. OBJECTIVE: We sought to determine whether ARC/AA severity relates to maladaptive responses to disease triggers. METHODS: Adults with HDM-associated ARC were challenged repetitively with HDMs in an aeroallergen challenge chamber. Mechanistic traits associated with disease severity were identified. RESULTS: HDM challenges evoked maladaptive (persistently higher ARC symptoms), adaptive (progressive symptom reduction), and resilient (resistance to symptom induction) phenotypes. Symptom severity in the natural environment was an imprecise correlate of the phenotypes. Nasal airway traits, defined by low inflammation-effectual epithelial integrity, moderate inflammation-effectual epithelial integrity, and higher inflammation-ineffectual epithelial integrity, were hallmarks of the resilient, adaptive, and maladaptive evoked phenotypes, respectively. Highlighting a crosstalk mechanism, peripheral blood inflammatory tone calibrated these traits: ineffectual epithelial integrity associated with CD8+ T cells, whereas airway inflammation associated with both CD8+ T cells and eosinophils. Hallmark peripheral blood maladaptive traits were increased natural killer and CD8+ T cells, lower CD4+ mucosal-associated invariant T cells, and deficiencies along the TLR-IRF-IFN antiviral pathway. Maladaptive traits tracking HDM-associated ARC also contributed to AA risk and severity models. CONCLUSIONS: Repetitive challenges with HDMs revealed that maladaptation to disease triggers may underpin ARC/AA disease severity. A combinatorial therapeutic approach may involve reversal of loss-of-beneficial-function traits (ineffectual epithelial integrity, TLR-IRF-IFN deficiencies), mitigation of gain-of-adverse-function traits (inflammation), and blocking of a detrimental crosstalk between the peripheral blood and airway compartments. Published by Elsevier Inc.
Authors: Irene den Otter; Luuk N A Willems; Annemarie van Schadewijk; Simone van Wijngaarden; Kirsten Janssen; Ronald C de Jeu; Jacob K Sont; Peter J Sterk; Pieter S Hiemstra Journal: Eur Respir J Date: 2016-05-26 Impact factor: 16.671
Authors: Jon R Konradsen; Anna James; Björn Nordlund; Lovisa E Reinius; Cilla Söderhäll; Erik Melén; Asa M Wheelock; Asa Wheelock; Karin C Lödrup Carlsen; Marika Lidegran; Marri Verhoek; Rolf G Boot; Barbro Dahlén; Sven Erik Dahlén; Gunilla Hedlin Journal: J Allergy Clin Immunol Date: 2013-04-26 Impact factor: 10.793
Authors: S O'Sullivan; L Cormican; J L Faul; S Ichinohe; S L Johnston; C M Burke; L W Poulter Journal: Am J Respir Crit Care Med Date: 2001-08-15 Impact factor: 21.405
Authors: Carole Ober; Zheng Tan; Ying Sun; Jennifer D Possick; Lin Pan; Raluca Nicolae; Sadie Radford; Rodney R Parry; Andrea Heinzmann; Klaus A Deichmann; Lucille A Lester; James E Gern; Robert F Lemanske; Dan L Nicolae; Jack A Elias; Geoffrey L Chupp Journal: N Engl J Med Date: 2008-04-09 Impact factor: 91.245
Authors: Akul Singhania; Joshua C Wallington; Caroline G Smith; Daniel Horowitz; Karl J Staples; Peter H Howarth; Stephan D Gadola; Ratko Djukanović; Christopher H Woelk; Timothy S C Hinks Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: Mihai G Netea; Leo A B Joosten; Eicke Latz; Kingston H G Mills; Gioacchino Natoli; Hendrik G Stunnenberg; Luke A J O'Neill; Ramnik J Xavier Journal: Science Date: 2016-04-21 Impact factor: 47.728
Authors: Christopher D Pascoe; Ma'en Obeidat; Bryna A Arsenault; Yunlong Nie; Stephanie Warner; Dorota Stefanowicz; Samuel J Wadsworth; Jeremy A Hirota; S Jasemine Yang; Delbert R Dorscheid; Chris Carlsten; Tillie L Hackett; Chun Y Seow; Peter D Paré Journal: BMC Pulm Med Date: 2017-12-11 Impact factor: 3.317
Authors: Alisha M Smith; Robert M Ramirez; Nathan Harper; Fabio Jimenez; Anne P Branum; Justin A Meunier; Lavanya Pandranki; Andrew Carrillo; Caitlyn Winter; Lauryn Winter; Cynthia G Rather; Daniel A Ramirez; Charles P Andrews; Marcos I Restrepo; Diego J Maselli; Jacqueline A Pugh; Robert A Clark; Grace C Lee; Alvaro G Moreira; Muthu Saravanan Manoharan; Jason F Okulicz; Robert L Jacobs; Sunil K Ahuja Journal: Allergy Date: 2021-10-22 Impact factor: 14.710